May 8, 2017 08:37 AM EDT

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

John Carroll

Editor & Founder

TherapeuticsMD already flagged that the FDA was about to reject its application for TX-004HR, a proposed new therapy to treat vaginal pain during intercourse …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

John Carroll

Editor & Founder

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Exclusive: Florida cancer biotech raises $100M Series A

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Nixed by the FDA, Ther­a­peu­tic­sMD is now plan­ning a long-shot bid to re­verse the de­ci­sion

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Exclusive: Florida cancer biotech raises $100M Series A

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned